Mylan Announces Intentions to Buy Sweden’s Meda for $7.2B

Generics giant Mylan N.V. has struck a tentative deal to purchase Swedish drugmaker Meda AB for $7.2 billion in cash and stock.
Source: International Pharmaceutical Regulatory Monitor